Ligand‐Enabled Pd‐Catalyzed sp 3 C−H Macrocyclization: Synthesis and Evaluation of Macrocyclic Sulfonamide for the Treatment of Parkinson's Disease
Angewandte Chemie International Edition · 04.11.2024 · 63 (45)
DOI: 10.1002/anie.202412296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 17.09.2024. Verfasst von Tongyu Bi und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Hauptthemen laut MEDLINE: Palladium, Sulfonamides, Parkinson Disease, Macrocyclic Compounds. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The development of simplified synthetic strategy to create structurally and functionally diverse pseudo‐natural macrocyclic molecules is highly appealing but poses a marked challenge. Inspired by natural scaffolds, herein, we describe a practical and concise ligand‐enabled Pd(II)‐catalyzed sp 3 C−H alkylation, olefination and arylation macrocyclization, which could offer a novel set of pseudo‐natural macrocyclic sulfonamides. Interestingly, the potential of ligand acceleration in C−H activation is also demonstrated by an unprecedented enantioselective sp 3 C−H alkylation macrocyclization. Moreover, a combination of in silico screening and biological evaluation led to the identification of a novel spiro‐grafted macrocyclic sulfonamide 2 a , which showed a promising efficacy for the treatment of Parkinson's disease (PD) in a mouse model through the activation of silent information regulator sirtuin 3 (SIRT3).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210000, China.
ORCID-Profile: Weibo Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bi, T., Cui, Y., Liu, S., Yu, H., Qiu, W., Hou, K. Q., Zou, J., Yu, Z., Zhang, F., Xu, Z., Zhang, J., Xu, X., & Yang, W. (2024). Ligand‐Enabled Pd‐Catalyzed sp 3 C−H Macrocyclization: Synthesis and Evaluation of Macrocyclic Sulfonamide for the Treatment of Parkinson's Disease. Angewandte Chemie International Edition, 63(45). https://doi.org/10.1002/anie.202412296
Vancouver
Bi T, Cui Y, Liu S, Yu H, Qiu W, Hou KQ, et al. Ligand‐Enabled Pd‐Catalyzed sp 3 C−H Macrocyclization: Synthesis and Evaluation of Macrocyclic Sulfonamide for the Treatment of Parkinson's Disease. Angewandte Chemie International Edition. 2024;63(45). doi:10.1002/anie.202412296
BibTeX
@article{Bi2024,
author = {Bi, Tongyu and Cui, Yunxia and Liu, Shuai and Yu, Haiyue and Qiu, Weirong and Hou, Ke-Qiang and Zou, Jiaqi and Yu, Zhipeng and Zhang, Feili and Xu, Zhongliang and Zhang, Jian and Xu, Xiaojun and Yang, Weibo},
title = {Ligand‐Enabled Pd‐Catalyzed sp 3 C−H Macrocyclization: Synthesis and Evaluation of Macrocyclic Sulfonamide for the Treatment of Parkinson's Disease},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {45},
doi = {10.1002/anie.202412296}
}
EUVIMED